The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer

Vasiliki, Tzelepi C.; Aristeidis, Gogadis T.; Christos, Adamidis K.; Timotheadou, Eleni T.

doi:10.2478/fco-2019-0007

Abstract

The emergence of cyclin-dependent kinase (CDK) 4 and 6 inhibitors has brought a new approach in the treatment of advanced hormone receptor (HR) positive breast cancer and human epidermal growth factor (HER) 2 negative breast cancer. To date, three CDK 4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, are approved by the Food and Drug Administration (FDA); the first two agents are approved by the European Medicines Agency (EMA) as well. The family of CDKs consists of key regulatory enzymes that play a significant role in cell cycle progression. The aim of this review is to give an overview of the mechanism of action and the efficacy of CDK4/6 inhibitors and to highlight the most serious adverse events and the drug interactions related to these agents.

References

D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: The next generation,” Cell, vol. 144, no. 5. Elsevier Inc., pp. 646–674, 2011.
Search in Google Scholar Back to article
G. H. Williams and K. Stoeber, “The cell cycle and cancer,” no. October 2011, pp. 352–364, 2012.
Search in Google Scholar Back to article
B. Cancer, “Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4 / 6 Inhibitors in Breast Cancer : Practical Considerations and Recommendations,” pp. 1–10, 2017.
Search in Google Scholar Back to article
S. Parylo and A. Vennepureddy, “Role of cyclin-dependent kinase 4 / 6 inhibitors in the current and future eras of cancer treatment,” no. May, 2018.
Search in Google Scholar Back to article
P. J. Roberts et al., “Multiple Roles of Cyclin-Dependent Kinase 4 / 6 Inhibitors in Cancer Therapy,” vol. 104, no. 6, 2012.
Search in Google Scholar Back to article
M. Malumbres and M. Barbacid, “Cell cycle, CDKs and cancer: a changing paradigm,” vol. 9, no. March, 2009.
Search in Google Scholar Back to article
R. A. Weinberg, “The Retinoblastoma Protein and Cell Cycle Control Review,” 1995.
Search in Google Scholar Back to article
K. E. Knudsen, E. Weber, K. C. Arden, W. K. Cavenee, J. R. Feramisco, and E. S. Knudsen, “The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms : inhibition of cell cycle progression and induction of cell death,” pp. 5239–5245, 1999.
Search in Google Scholar Back to article
S. Thomas and A. Balan, “Retinoblastoma Tumor Suppressor Gene : An Overview,” no. January 2012, 2014.
Search in Google Scholar Back to article
L. N. Kent and G. Leone, “The broken cycle : E2F dysfunction in cancer,” Nat. Rev. Cancer, vol. 19, no. June, 2019.
Search in Google Scholar Back to article
T. W. Miller, “Clinical potential of novel therapeutic targets in breast cancer : CDK4 / 6, Src, JAK / STAT, PARP, HDAC, and PI3K / AKT / mTOR pathways,” pp. 203–215, 2014.
Search in Google Scholar Back to article
S. Pernas, S. M. Tolaney, E. P. Winer, and S. Goel, “CDK4/6 inhibition in breast cancer: current practice and future directions,” Ther. Adv. Med. Oncol., vol. 10, pp. 1–15, 2018.
Search in Google Scholar Back to article
S. L. Sammons, D. L. Topping, and K. L. Blackwell, “HR+, HER2–Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles,” pp. 637–649, 2017.
Search in Google Scholar Back to article
M. Thill and M. Schmidt, “Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer,” Therapeutic Advances in Medical Oncology, vol. 10. SAGE Publications Inc., 01-Jan-2018.
Search in Google Scholar Back to article
C. K. Osborne and R. Schiff, “Mechanisms of Endocrine Resistance in Breast Cancer,” Annu. Rev. Med., vol. 62, no. 1, pp. 233–247, Jan. 2010.
Search in Google Scholar Back to article
D. L. Burkhart and J. Sage, “Cellular mechanisms of tumour suppression by the retinoblastoma gene,” Nature Reviews Cancer, vol. 8, no. 9. pp. 671–682, Sep-2008.
Search in Google Scholar Back to article
E. S. Knudsen and J. Y. J. Wang, “Targeting the RB-pathway in cancer therapy,” Clin. Cancer Res., vol. 16, no. 4, pp. 1094–1099, Feb. 2010.
Search in Google Scholar Back to article
A. Johnson and J. M. Skotheim, “NIH Public Access,” vol. 25, no. 6, pp. 1–12, 2014.
Search in Google Scholar Back to article
No Title. .
Search in Google Scholar Back to article
Y. J. Choi and L. Anders, “Signaling through cyclin D-dependent kinases,” Oncogene, vol. 33, no. 15. Nature Publishing Group, pp. 1890–1903, 10-Apr-2014.
Search in Google Scholar Back to article
E. A. Musgrove, C. E. Caldon, J. Barraclough, A. Stone, and R. L. Sutherland, “Cyclin D as a therapeutic target in cancer,” Nat. Publ. Gr., vol. 11, no. 8, pp. 558–572, 2011.
Search in Google Scholar Back to article
J. Lukas, J. Bartkova, and J. Bartek, “Convergence of Mitogenic Signalling Cascades from Diverse Classes of Receptors at the Cyclin D – Cyclin-Dependent Kinase – pRb-Controlled G 1 Checkpoint,” vol. 16, no. 12, pp. 6917–6925, 1996.
Search in Google Scholar Back to article
E. S. Knudsen and E. Zacksenhaus, “The vulnerability of RB loss in breast cancer : Targeting a void in cell cycle control,” vol. 9, no. 57, pp. 30940–30941, 2018.
Search in Google Scholar Back to article
C. A. Lange and D. Yee, “NIH Public Access,” vol. 18, no. 4, pp. 1–8, 2014.
Search in Google Scholar Back to article
D. W. Fry et al., “Specific inhibition of cyclin-dependent kinase 4 / 6 by PD 0332991 and associated antitumor activity in human tumor xenografts,” vol. 3, no. November, pp. 1427–1438, 2004.
Search in Google Scholar Back to article
F. Petrelli et al., “Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials,” Breast Cancer Research and Treatment, Springer New York LLC, 30-Apr-2019.
Search in Google Scholar Back to article
G. K. Schwartz et al., “Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2 / 1),” pp. 1862–1868, 2011.
Search in Google Scholar Back to article
A. Demichele et al., “Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer,” pp. 1–11, 2018.
Search in Google Scholar Back to article
R. S. Finn et al., “The cyclin-dependent kinase 4 / 6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1 / TRIO-18): a randomised phase 2 stud,” Lancet Oncol., pp. 1–11.
Search in Google Scholar Back to article
H. S. R. R. S. F. V Diéras, J. E. O. Lipatov, A. A. J. N. Harbeck, and A. C. S. Iyer, “Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive / human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up,” Breast Cancer Res. Treat., vol. 174, no. 3, pp. 719–729, 2019.
Search in Google Scholar Back to article
N. C. Turner et al., “Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer,” N. Engl. J. Med., vol. 373, no. 3, pp. 209–219, Jul. 2015.
Search in Google Scholar Back to article
H. Iwata et al., “PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients,” J. Glob. Oncol., vol. 3, no. 4, pp. 289–303, Aug. 2017.
Search in Google Scholar Back to article
G. N. Hortobagyi et al., “Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer,” N. Engl. J. Med., vol. 375, no. 18, pp. 1738–1748, 2016.
Search in Google Scholar Back to article
G. N. Hortobagyi et al., “Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Original article,” no. April, pp. 1541–1547, 2018.
Search in Google Scholar Back to article
G. Curigliano et al., “Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study,” Breast, vol. 28, pp. 191–198, Aug. 2016.
Search in Google Scholar Back to article
D. J. Slamon et al., “JOURNAL OF CLINICAL ONCOLOGY Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3,” J Clin Oncol, vol. 36, pp. 2465–2472, 2018.
Search in Google Scholar Back to article
O. Article, “Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer,” pp. 1–10, 2019.
Search in Google Scholar Back to article
E. C. Ehman et al., “HHS Public Access,” vol. 46, no. 5, pp. 1247–1262, 2017.
Search in Google Scholar Back to article
G. W. Sledge et al., “MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy,” J. Clin. Oncol., vol. 35, no. 25, pp. 2875–2884, 2017.
Search in Google Scholar Back to article
M. P. Goetz et al., “MONARCH 3 : Abemaciclib As Initial Therapy for Advanced Breast Cancer,” vol. 35, no. 32, 2019.
Search in Google Scholar Back to article
S. Johnston et al., “MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer,” npj Breast Cancer, vol. 5, no. 1, Dec. 2019.
Search in Google Scholar Back to article
N. Masuda, K. Inoue, R. Nakamura, Y. Rai, H. Mukai, and S. Ohno, “Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : PALOMA-3 subgroup analysis of Japanese patients,” Int. J. Clin. Oncol., vol. 0, no. 0, p. 0, 2018.
Search in Google Scholar Back to article
K. Gelmon et al., “new england journal,” pp. 1925–1936, 2016.
Search in Google Scholar Back to article
J. K. Kish et al., “Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced / metastatic breast cancer treated in community oncology practice in the USA one year post approval,” pp. 1–8, 2018.
Search in Google Scholar Back to article
US Food and Drug Administration, “Ibrance. Prescribing information.,” Https://Www.Accessdata.Fda.Gov/Drugsatfda_Docs/Label/2017/207103S004Lbl.Pdf 2017.
Search in Google Scholar Back to article
CHMP, “ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS.”
Search in Google Scholar Back to article
Epar, “ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS.”
Search in Google Scholar Back to article
C. Van Noord, M. Eijgelsheim, and B. H. C. Stricker, “Drug- and non-drug-associated QT interval prolongation,” British Journal of Clinical Pharmacology, vol. 70, no. 1. pp. 16–23, Jul-2010.
Search in Google Scholar Back to article
J. C. Chappell et al., “Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate,” Clinical Pharmacology and Therapeutics, Nature Publishing Group, 2019.
Search in Google Scholar Back to article

The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer

Abstract

Paradigm

My account